Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
denovoDerm and denovoSkin for Large Skin Defects
NCT02145130Phase 1Completed
- Sponsor
- University of Zurich
- Start
- May 2014
- Primary completion
- Mar 2021
- Modality
- Implantable Devices, Implantable Hydrogels, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of DenovoDerm and denovoSkin in burn injury, soft tissue injury, skin necrosis and 3 more (2 arms), sponsored by University of Zurich. Primary endpoint: Safety of denovoDerm and denovoSkin at 21 days. Started May 2014; status: completed.
02
Drugs
DenovoDermdenovoSkin
03
Conditions
burn injurysoft tissue injuryskin necrosisscarCongenital melanocytic nevus (CMN)
Beyond the preview
Go deeper on NCT02145130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02145130.